Abstract:The potential estrogenic activities of perfluoroalkyl substances (PFASs) are controversial. Here, we investigated the estrogenic/antiestrogenic activities of PFASs and explored the corresponding interaction mode of PFASs with the estrogen receptor (ER) by combining in vitro assays and in silico modeling. We found that three PFASs (perfluorobutanoic acid, perfluorobutane sulfonate, and perfluoropentanoic acid) exerted antiestrogenic effects by inhibiting luciferase activity, whereas perfluorohexane sulfonate (PFHxS) and perfluorooctane sulfonate (PFOS) exerted estrogenic effects by inducing luciferase activity. When coexposed to 17β-estradiol (E2), all tested PFASs attenuated the E2-stimulated luciferase activity; unexpectedly, each PFAS could further attenuate the luciferase activity generated by the cotreatment with ICI 182,780 and E2, with a minimal effective concentration comparable to that found in human serum. PFHxS and PFOS significantly induced the gene expression of TFF1; additionally, all PFASs inhibited the E2-induced gene expression of TFF1 and EGR3. Furthermore, the results of the blind docking analyses suggested that the interaction with the coactivator-binding region on the ER surface should be included as a pathway through which PFASs exert estrogenic and antiestrogenic activities. Finally, we revealed the critical molecular property of the zero-order molecular connectivity index (MCI) (0χ) that affects the antiestrogenic activity of PFASs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.est.0c03468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.est.0c03468</a>.Structures of tested chemicals (Table S1); concentrations of PFASs in exposure solutions (Table S2); binding free energy components of E2 and PFOS in the ER–E2–PFOS complex (Table S3); compounds, parameters, and activity data (Table S4); RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) (part 1); in silico computational model (part 2); concentration–response luciferase activity of PFASs that gave a minor response in the MVLN assay (Figure S1); ERE-luciferase assay of PFASs in MVLN cells after cotreatment with E2 and ICI 182,780 (Figure S2); binding modes of 10 PFASs molecules in HIP molecular modeling (Figure S3); binding modes of 10 PFASs molecules in HIE molecular modeling (Figure S4); RMSD changes in MD simulations (Figure S5); and empirical distribution of R2* for the pEC50 model (Figure S6) (<a class="ext-link" href="/doi/suppl/10.1021/acs.est.0c03468/suppl_file/es0c03468_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

In vitro screening of understudied PFAS with a focus on lipid metabolism disruption

Impact of perfluoroalkyl substances (PFAS) and PFAS mixtures on lipid metabolism in differentiated HepaRG cells as a model for human hepatocytes

Investigating mouse hepatic lipidome dysregulation following exposure to emerging per- and polyfluoroalkyl substances (PFAS)

Hepatic Transcriptome Comparative in Silico Analysis Reveals Similar Pathways and Targets Altered by Legacy and Alternative Per- and Polyfluoroalkyl Substances in Mice

Legacy and alternative per- and polyfluoroalkyl substances (PFAS) alter the lipid profile of HepaRG cells

Metabolic and phenotypic changes induced by PFAS exposure in two human hepatocyte cell models

Risk-based prioritization of PFAS using phenotypic and transcriptomic data from human induced pluripotent stem cell-derived hepatocytes and cardiomyocytes

Transcriptomic re-analyses of human hepatocyte spheroids treated with PFAS reveals chain length and dose-dependent modes of action

Hazard and Risk Characterization of 56 Structurally Diverse PFAS Using a Targeted Battery of Broad Coverage Assays Using Six Human Cell Types.

Evaluation of the Estrogenic/Antiestrogenic Activities of Perfluoroalkyl Substances and Their Interactions with the Human Estrogen Receptor by Combining In Vitro Assays and In Silico Modeling

In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs)

Screening of Potential PFOS Alternatives To Decrease Liver Bioaccumulation: Experimental and Computational Approaches.

Hazard and Risk Characterization and Grouping of 56 Structurally Diverse PFAS Using a Targeted Battery of Broad Coverage Assays in Six Human Cell Types

PPARα/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per- and polyfluoroalkyl substances: An integrated approach

Probing the hepatotoxicity mechanisms of novel chlorinated polyfluoroalkyl sulfonates to zebrafish larvae: Implication of structural specificity

Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl substances (PFAS) results in sex-dependent modulation of cholesterol metabolism and liver injury

Exposure to PFAS chemicals induces sex-dependent alterations in key rate-limiting steps of lipid metabolism in liver steatosis

A systems toxicology approach for identification of disruptions in cholesterol homeostasis after aggregated exposure to mixtures of perfluorinated compounds in humans

Category-Based Toxicokinetic Evaluations of Data-Poor Per- and Polyfluoroalkyl Substances (PFAS) using Gas Chromatography Coupled with Mass Spectrometry

Integrating high-throughput phenotypic profiling and transcriptomic analyses to predict the hepatosteatosis effects induced by per- and polyfluoroalkyl substances

Interspecies comparison of metabolism of two novel prototype PFAS